The biologics manufacturing market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

Order report at
https://www.thebusinessresearchcompany.com/report/biologics-global-market-opportunities-and-strategies-to-2021

Biologics Market Size

The global biologics market grew at a compound annual growth rate (CAGR) of about 5.5%. This growth can be attributed to technological advances in research and development of biologics around the world. Intensive research in novel therapies and combination therapies for the treatment of a wide range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration and hematological malignancies has led to the development of a range of new products and contributed to the biologics market growth.

North America was the largest region in the biologics market in 2017, accounting for about 40% of the market. This can be attributed to the high per capita healthcare expenditure in the region and the investment in novel treatments leading to the early adoption of new anti-inflammatory, anti-cancer and anti-viral biologics in the region. Pricing levels for drugs in the US are also some of the highest globally.

Download sample report at
https://www.thebusinessresearchcompany.com/sample.aspx?id=792&type=smp

The North American biologics market is expected to grow from $87.3 billion in 2017 to $135.9 billion in 2021. The steep increase in the growth rate of the market during 2017-2021 can be attributed to support from governments to increase awareness about the safety and efficacy of biologics in the treatment of rare and chronic diseases and also the increasing prevalence of these rare diseases is expected to enhance the growth of the biologics market.

Monoclonal antibodies and therapeutic proteins dominate the market for biologics in North America, with a market value of $40 billion and $33 billion respectively in 2017. The vaccine market was worth about $15 billion in 2017.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company